About Us Executive Leadership

Evan Picard

Chief Financial Officer

Evan’s leadership journey has seen him play pivotal roles in shaping business strategies across multiple industries. Before joining MMS, Evan was Vice President of Finance at Parexel, having previously made significant contributions to renowned entities such as Syneos Health, PRA Health Sciences, and RTI International. His ability to forge strong teams and provide forward-looking insights positions him as a cornerstone of MMS’s future growth.

As Chief Financial Officer of MMS, Evan serves as the global head of the Accounting, Finance, Human Resources, and Talent Acquisition functions. Evan and his team are responsible for: financial planning and analysis, consolidations under US GAAP, treasury, HR leadership, and recruiting services. Evan’s role underscores MMS Holdings’ commitment to top-tier financial stewardship, talent development, and MMS’ growth-oriented mindset. His unique blend of experience and acumen promises to steer the company toward continued financial success.

What we have here at MMS is very special. We have great staff who deliver day in and day out for our clients and our organization. The expertise we bring to the market is top tier, and it shows through our customer satisfaction scores and our customer retention rates. In my organization, we aim to provide high quality services and solutioning for our internal and external partners. My team accomplishes this by exemplifying our corporate values, like “Wow the Customer” and “SOUL” (Sense Of Urgency Leadership). I’m very proud of the work we do at MMS and I’m excited to continue on our journey of evolution and growth as a company delivering value to our clients and bringing new therapies to patients swiftly and creatively.

Evan Picard

Chief Financial Officer

Evan has a BS – Management degree from Virginia Tech (Pamplin College of Business) and an MBA from the College of William & Mary (Mason School of Business).

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules